Eric R. Fedyk

Takeda (United States) — United States

Immunology and Microbiology · Life Sciences

19h-index2.4kcitations46works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(11), T-cell and B-cell Immunology(10), Asthma and respiratory diseases(7), Inflammatory Bowel Disease(6), Immune Response and Inflammation(6)

Publications46 total

A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Single‐Dose and Multiple‐Rising‐Dose Study of the BTK Inhibitor TAK‐020 in Healthy Subjects
Clinical and Translational Science·2021· 6 citedOpen Access
Mezagitamab Induces Immunomodulatory Effect in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Blood·2020· 4 cited
Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
British Journal of Clinical Pharmacology·2020· 39 citedOpen Access
Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
Blood·2019· 26 cited
The Binding of CD38 Therapeutics to Red Blood Cells and Platelets Subverts Depletion of Target Cells
Blood·2019· 3 cited
A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys
Journal of Pharmacology and Experimental Therapeutics·2019· 25 citedOpen Access
A Single Administration of the Cytolytic CD38 Antibody TAK-079 to Healthy Subjects: Tolerability, Pharmacokinetics and Pharmacodynamics
Blood·2018· 6 cited
SAT0226 A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-rising dose study of the btk inhibitor tak-020 in healthy volunteers
Annals of the Rheumatic Diseases·2018· 3 citedOpen Access
Pharmacokinetics and pharmacodynamics of the cytolytic anti‐<scp>CD</scp>38 human monoclonal antibody <scp>TAK</scp>‐079 in monkey – model assisted preparation for the first in human trial
Pharmacology Research & Perspectives·2018· 12 citedOpen Access
MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model
International Immunopharmacology·2018· 30 cited
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab
Clinical Pharmacokinetics·2017· 151 citedOpen Access
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
Journal of Crohn s and Colitis·2016· 262 cited
Regulation of B Cell Tolerance and Triggering by Immune Complexes
Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy·2015· 3 cited
In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes
mAbs·2013· 58 citedOpen Access
P025 Vedolizumab does not affect the suppressive activity of gut-homing T regulatory cells
Journal of Crohn s and Colitis·2013Open Access
Antagonizing the α4β1 Integrin, but Not α4β7, Inhibits Leukocytic Infiltration of the Central Nervous System in Rhesus Monkey Experimental Autoimmune Encephalomyelitis
The Journal of Immunology·2013· 79 citedOpen Access
Vedolizumab Does Not Affect the Suppressive Activity of Gut-homing T Regulatory Cells
Inflammatory Bowel Diseases·2012· 2 citedOpen Access
Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates
Inflammatory Bowel Diseases·2012· 138 citedOpen Access
P019 Internalization of the vedolizumab/α4β7 complex and kinetics of restoring functional activity
Journal of Crohn s and Colitis·2012· 1 citedOpen Access
Internalization of the vedolizumab/α4β7 complex and kinetics of restoring functional activity
Inflammatory Bowel Diseases·2011
page 1 of 3Next →

Frequent Co-authors

Vivek J. Kadambi(9), Lili Yang(8), Tim Wyant(8), Richard P. Phipps(8), Vilmos Csizmadia(5), Deborah M. Brown(5), Glennda Smithson(5), Catherine Milch(4), Irving H. Fox(4), Martin R. Hodge(4), Jose Estevam(4), Deborah Berg(4), T. Wyant(4), Dulce Soler(3), Kristine Burke(3), Gëzim Lahu(3), Antonio Palumbo(3), Carl L. Alden(3), Lachy McLean(3), Melinda A. Borrello(3)